Aptevo Therapeutics (APVO) Announces 1:37 Reverse Share Split

Aptevo Therapeutics Inc. (NASDAQ: APVO) today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-37 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on December [3], 2024 at 5:01 p.m. Eastern Time (the "Effective Time"), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on December [4], 2024. In connection with the Reverse Stock Split, every 37 shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock, "APVO", in connection with the reverse split.

The Reverse Stock Split is part of the Company's plan to regain compliance with the minimum bid price requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.

The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on October 25, 2024 (the "Special Meeting") to be effected in the Board's discretion within approved parameters. Following the Special Meeting, the final ratio was approved by the Company's Board on October 25, 2024.

The Reverse Stock Split will reduce the number of shares of the Company's outstanding common stock from approximately 18.5 million shares (as of the date of this press release, when including issuances in process) to approximately 0.5 million shares, subject to adjustment for rounding, as discussed below and potential additional issuances through the effective date of the Reverse Stock Split.

The reverse split will affect all issued and outstanding shares of common stock. All outstanding options, restricted stock units, warrants, and other securities entitling their holders to purchase or otherwise receive shares of common stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under the Company's equity incentive plans will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.001 par value per share. The reverse split will not change the authorized number of shares of common stock or preferred stock. No fractional shares will be issued in connection with the reverse split, and stockholders who would otherwise be entitled to receive a fractional share of Common Stock, the Company will round up to the next whole share.

Additional information regarding the reverse stock split is available in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission (SEC) on October 3, 2024 and a Current Report on Form 8-K which the Company plans to file following the Effective Time.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Breeze Acquisition Corp. II gets Nasdaq notice for late 10-Q filings
• RenovoRx regains Nasdaq minimum bid price compliance